Chengdu Kanghong Pharmaceutical Group

Chengdu Kanghong Pharmaceutical Group is a leading Chinese pharmaceutical company specializing in the research, development, and commercialization of innovative drugs, particularly in the fields of ophthalmology, central nervous system (CNS), and digestive health. Founded in 1996, the company has grown into a major player in the Chinese biotech landscape, known for its flagship biological product, Conbercept (Lumitin), a VEGF inhibitor used to treat retinal diseases. The company operates with a strong focus on 'integrated research, production, and sales,' maintaining multiple GMP-certified manufacturing sites and a robust R&D infrastructure. In recent years, Kanghong has aggressively expanded into advanced modalities, including AAV-based gene therapies and antibody-drug conjugates (ADCs), while maintaining a significant portfolio of traditional Chinese medicines (TCM) and chemical generics.